GW&K Investment Management LLC grew its holdings in Bruker Co. (NASDAQ:BRKR) by 42.0% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 118,164 shares of the medical research company’s stock after buying an additional 34,953 shares during the quarter. GW&K Investment Management LLC’s holdings in Bruker were worth $4,055,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Bank of Montreal Can raised its stake in shares of Bruker by 346.7% in the 4th quarter. Bank of Montreal Can now owns 3,708 shares of the medical research company’s stock valued at $128,000 after buying an additional 2,878 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Bruker in the 2nd quarter valued at $111,000. Zions Bancorporation acquired a new position in shares of Bruker in the 3rd quarter valued at $119,000. The Manufacturers Life Insurance Company raised its stake in shares of Bruker by 7.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 5,003 shares of the medical research company’s stock valued at $144,000 after buying an additional 331 shares in the last quarter. Finally, Advisory Services Network LLC raised its stake in shares of Bruker by 6.3% in the 2nd quarter. Advisory Services Network LLC now owns 6,847 shares of the medical research company’s stock valued at $197,000 after buying an additional 406 shares in the last quarter. Institutional investors own 65.60% of the company’s stock.

Shares of Bruker Co. (NASDAQ BRKR) opened at $35.07 on Tuesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.60 and a quick ratio of 1.60. The firm has a market cap of $5,475.81, a PE ratio of 37.31, a price-to-earnings-growth ratio of 2.65 and a beta of 1.12. Bruker Co. has a 1 year low of $21.83 and a 1 year high of $36.53.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Thursday, November 2nd. The medical research company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.02. The firm had revenue of $435.60 million during the quarter, compared to analysts’ expectations of $415.45 million. Bruker had a net margin of 8.85% and a return on equity of 25.83%. The company’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same quarter last year, the company posted $0.32 EPS. equities research analysts forecast that Bruker Co. will post 1.19 earnings per share for the current fiscal year.

BRKR has been the subject of a number of recent research reports. Goldman Sachs Group restated a “sell” rating and issued a $24.00 price objective on shares of Bruker in a research note on Tuesday, September 26th. JPMorgan Chase & Co. upgraded shares of Bruker from an “underweight” rating to a “neutral” rating and set a $28.00 target price for the company in a research report on Friday, November 3rd. Bank of America upgraded shares of Bruker from an “underperform” rating to a “neutral” rating and set a $34.00 target price for the company in a research report on Friday, November 3rd. Cowen reiterated a “hold” rating and set a $29.00 target price on shares of Bruker in a research report on Friday, November 3rd. Finally, Citigroup increased their target price on shares of Bruker from $29.00 to $34.00 and gave the stock a “neutral” rating in a research report on Friday, November 3rd. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and five have assigned a buy rating to the company. Bruker presently has a consensus rating of “Hold” and an average target price of $32.38.

ILLEGAL ACTIVITY NOTICE: This report was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://theolympiareport.com/2018/01/23/gwk-investment-management-llc-acquires-34953-shares-of-bruker-co-brkr.html.

Bruker Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Co. (NASDAQ:BRKR).

Institutional Ownership by Quarter for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.